SF3B1 and BAP1 mutations in blue nevus-like melanoma
Klaus Griewank(German Cancer Research Center), Dirk Schadendorf(University of Mannheim)
Cited by 101
Related Papers
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
|Nature Medicine|2019|1.1k
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition
|Journal of Clinical Oncology|2012|225
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi
|Modern Pathology|2016|71
Dose-dependent severe cutaneous reactions to imatinib
|British Journal of Cancer|2003|39